Scios Presenting Natrecor Cost Data Vs. Dobutamine At HFSA Meeting
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Scios will present economic data for its injectable acute decompensated heart failure drug Natrecor (nesiritide) in early September suggesting a potential 30% savings in initial hospital costs compared to dobutamine.